Regenstrief Institute research scientist Noll Campbell, PharmD, M.S., recently contributed to a study that made national headlines and provided more evidence that anticholinergic medications are linked to cognitive decline.
The results from the study, led by researchers at the University of California San Diego School of Medicine, were published in Neurology. The authors concluded that anticholinergics are associated with an increased risk of cognitive decline regardless of the presence of genetic or biomarker risk factors for Alzheimer’s disease.
Dr. Campbell consulted on the study, providing perspective on the data based on similar studies he has been involved with at Regenstrief and Indiana University School of Medicine. He is listed as an author on the paper.
The past research conducted by Dr. Campbell and his colleagues also provides evidence establishing a link between the common type of medication and cognitive decline. He is now leading a clinical trial to determine if deprescribing anticholinergics improves cognition, which could in turn delay or prevent dementia.
In addition to his role as a research scientist at Regenstrief Institute, Dr. Campbell is an assistant professor of pharmacy practice at the Purdue University College of Pharmacy.
